KRYS Krystal Biotech, Inc.
Healthcare$302.68+1.08%ClosedMarket Cap: $8.92B
As of 2026-05-26
Valuation
P/E (TTM)
36.96
PEG
0.28
P/B
6.87
P/S
21.15
EV/EBITDA
44.91
DCF Value
$546.96
FCF Yield
2.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.8%
Operating Margin
42.8%
Net Margin
53.9%
ROE
19.3%
ROA
16.1%
ROIC
13.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $116.4M | 94.6% | $53.7M | $55.9M | $— | — |
| Q4 null | $107.1M | 89.8% | $44.4M | $51.4M | $— | — |
| FY null | $389.1M | 92.6% | $161.3M | $204.8M | $— | — |
| Q3 null | $97.8M | 94.2% | $41.4M | $79.4M | $— | — |
| Q2 null | $96.0M | 92.5% | $39.3M | $38.3M | $— | — |
| Q1 null | $88.2M | 94.3% | $36.2M | $35.7M | $— | — |
| Q4 null | $91.1M | 94.6% | $41.4M | $45.5M | $— | — |
| FY null | $290.5M | 93.1% | $65.7M | $89.2M | $— | — |
| Q3 null | $83.8M | 92.0% | $22.4M | $27.2M | $— | — |
| Q2 null | $70.3M | 91.5% | $8.6M | $15.6M | $— | — |
| Q1 null | $45.3M | 94.7% | $-6.7M | $932.0K | $— | — |
| Q4 2023 | $42.1M | 89.6% | $3.1M | $8.7M | $0.30 | — |